603882.SH
Guangzhou Kingmed Diagnostics Group Co., Ltd.
SSE · Healthcare · Medical - Diagnostics & Research · CN
CNY 29.73
−5.17%Year over year
Reported trailing growth
- Revenue
- -13.2%
- EBITDA
- —
- EBIT
- +90.4%
- EPS
- +73.9%
- Free cash flow
- +19.0%
- Operating cash flow
- +8.3%
Forward estimates
Based on analyst estimates
- Revenue
- +14.1%
- EBITDA
- +258.4%
- EPS
- +547.9%
Three-year CAGR
- Revenue
- -27.0%
- EBITDA
- -58.0%
- EBIT
- +52.5%
- Net income
- +54.6%
- EPS
- +54.9%
- Free cash flow
- -11.1%
Reported trailing growth, forward expectations and three-year compound growth rates · Data as of Mar 1, 2026